SPRINT

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Retrieved on: 
星期三, 四月 17, 2024
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Safety, ESCMID, Political moderate, SPRINT, ECCMID, Medication, Virology, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.
  • The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.
  • Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

Retrieved on: 
星期一, 四月 8, 2024
Surgeon, Orthopedic surgery, Science, Partnership, Risk, International, Dislocation, SVP, Patient, Hospital, Registry, Senior, SPRINT, SNN, Elective surgery, THA

Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty

Key Points: 
  • Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty
    Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney.
  • This exclusive distribution builds upon the agreement Smith+Nephew announced for Japan in April 2023.
  • Lynette Walter, NAVBIT’s CEO said, “We are absolutely delighted to expand our partnership with Smith+Nephew into the Australian market.
  • Today we have higher expectations around the accuracy and precision of our surgery,” said Professor Bill Walter, Orthopaedic Surgeon and Founder of NAVBIT.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Retrieved on: 
星期二, 三月 26, 2024
OCT, Optical coherence tomography, Patent, Multiple sclerosis, Capsule, Tablet, Code, MD, SPRINT, MPH, Tokyo Stock Exchange, Pharmaceutical industry

Once issued, this patent is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than October 2039.
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.

SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System

Retrieved on: 
星期四, 二月 1, 2024
SPRINT, Growth, Chronic pain, SPR, PNS, Knee, Patient, Pain, Shoulder, Head, Investment, Venture round, Neck, Medtech, Therapy, Quality of life

The equity financing was led by Revelation Partners, SPR’s lead investor of the Series D equity financing, and incumbent investors, RC Capital and Mutual Capital Partners.

Key Points: 
  • The equity financing was led by Revelation Partners, SPR’s lead investor of the Series D equity financing, and incumbent investors, RC Capital and Mutual Capital Partners.
  • The debt facility is provided by SLR Capital Partners and Armentum Partners served as the Company’s financial advisor.
  • The funds will be used to capitalize on commercial momentum, customer demand, and market opportunity to expand SPR sales representation in additional U.S. sales territories.
  • “We thank our financing partners and are pleased to raise additional capital to support and accelerate our already significant growth,” said Maria Bennett, President, CEO and Founder of SPR Therapeutics.

WDA Expands Ownership Group with Second Female Leader

Retrieved on: 
星期三, 一月 31, 2024
SPRINT, San Francisco Bay Area, SAN, UCSF, Lead, Marketing, AEC, Commercial Real Estate Women, Community practice, Alaska Airlines, WDA, SJSU, Business development, Super Duper, Commerce, Thought, CREW, Female, Woman, Management

SAN FRANCISCO, Jan. 31, 2024 /PRNewswire/ -- William Duff Architects (WDA) has expanded its ownership to include Sarah Mergy, Director of Business Development and Marketing. Sarah joined the firm five short years ago but has quickly made an impact. She joins Phoebe Lam, Director of Operations, as the second female owner.

Key Points: 
  • SAN FRANCISCO, Jan. 31, 2024 /PRNewswire/ -- William Duff Architects (WDA) has expanded its ownership to include Sarah Mergy , Director of Business Development and Marketing.
  • She joins Phoebe Lam , Director of Operations, as the second female owner.
  • Sarah's professional career in the A/E/C industry spans over 20 years' experience in operations, marketing, design and business development.
  • At WDA, she is also a member of the firm's Management team working to drive growth-oriented marketing and business strategy.

Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress Its Proprietary CCR8 Antibody Candidate to the Clinic

Retrieved on: 
星期四, 一月 25, 2024
Technology, Biotechnology, Health, Biometrics, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Other Science, Research, Hospitals, Health Technology, Science, Clinical Trials, Patient, Therapy, G protein-coupled receptor, AP-HP, Multimedia, Fatigue, Intelligence, Medicen, Government, Cancer, Cutaneous T-cell lymphoma, Drug discovery, Quality of life, SPRINT, Survival rate, Regulatory T cell, National Cancer Institute, Disease, Study Group, Sarcoma, Hospital, GPCR, Pain, Gq alpha subunit, ANR, TME, RHU, Physician, Pharmaceutical industry

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.
  • View the full release here: https://www.businesswire.com/news/home/20240125583037/en/
    The SPRINT project aims to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care.
  • The grant that we have been awarded by the RHU SPRINT consortium will support the progress of DT-7012, an anti-CCR8 monoclonal antibody which has incredible potential as a best-in-class therapeutic, into the clinic.
  • Domain was already awarded a first RHU grant, RHU CONDOR for Sarcoma, in the previous campaign, leveraging another proprietary asset.

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Retrieved on: 
星期三, 一月 17, 2024
Capsule, MD, Tokyo Stock Exchange, Multiple sclerosis, Code, SPRINT, Tablet, OCT, Patent, MPH, Optical coherence tomography, Pharmaceutical industry

The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.

Key Points: 
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.
  • We are very pleased to receive a notice of this new patent which covers China and we believe it could increase the potential value of MN-166.”

SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024

Retrieved on: 
星期二, 一月 16, 2024
Permanent, Sutter Health, Assistant, Hope, Patient, PNS, Therapy, Research, NANS, Knee, Medicare, Foot, Poster, Ankle, Groin, Section, Pain, SPRINT, NP-hardness, Shoulder, CRPS, SPR, Treatment, Abstract, Physician, Nursing

CLEVELAND, Jan. 16, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society (NANS) Annual Meeting January 18-21 in Las Vegas.

Key Points: 
  • CLEVELAND, Jan. 16, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society (NANS) Annual Meeting January 18-21 in Las Vegas.
  • A total of 11 abstracts highlighting applications of the SPRINT® PNS System will be featured at the meeting including four posters never before presented to the industry.
  • The presentation reviews treatment costs for patients in two cohorts who started treatment either with SPRINT PNS or with a conventional brief PNS trial.
  • The poster reviews health economics and outcomes research to explore the economic implications of the use of SPRINT PNS in chronic low back pain.

SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT® PNS System for Low Back Pain

Retrieved on: 
星期二, 十二月 12, 2023
Clinical trial, Chronic pain, LBP, Treatment, Human back, Pain, Doctor of Philosophy, Therapy, Randomness, Control, Randomized controlled trial, PNS, SPRINT, Back pain, Face, Patient, Safety, Clinical, RCT, SPR, Pharmaceutical industry

CLEVELAND, Dec. 12, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. today announced the final patient was enrolled in the RESET Clinical Trial of SPRINT® PNS for the treatment of chronic low back pain (LBP).

Key Points: 
  • CLEVELAND, Dec. 12, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. today announced the final patient was enrolled in the RESET Clinical Trial of SPRINT® PNS for the treatment of chronic low back pain (LBP).
  • This large multicenter randomized controlled trial (RCT) compares percutaneous peripheral nerve stimulation (PNS) with standard interventional treatments of chronic LBP.
  • The “RESET Clinical Trial: A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain” is a large RCT being conducted at more than 20 clinical centers across the United States.
  • “We are thrilled to announce the completion of enrollment in this important study, which is the largest randomized controlled trial to date studying the SPRINT PNS System.

New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023

Retrieved on: 
星期一, 十一月 13, 2023
Twilight anesthesia, Spondylosis, ASRA, Safety, TKA, Chronic pain, End, Bandage, Therapy, Adhesive, Spine, SPR, Patient, Cohort (statistics), PNS, Pain management, Joint, Pain, Diagnosis, Randomized controlled trial, Medicare, Society, Skin, Quality of life, Neuropathic pain, SPRINT, Dentistry, Treatment

CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- At the 22nd Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in New Orleans, three posters on the SPRINT® PNS System were shared for the first time.

Key Points: 
  • CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- At the 22nd Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in New Orleans, three posters on the SPRINT® PNS System were shared for the first time.
  • The first poster, “Percutaneous PNS Relieves Persistent Postoperative Pain and Improves Function after TKA: Results from a Placebo-Controlled Randomized Controlled Trial” was recognized with a President’s Choice Award from ASRA.
  • This poster highlights the results from a prospective trial evaluating the impact of SPRINT peripheral nerve stimulation (PNS) used for chronic knee pain after total knee arthroplasty (TKA) surgery.
  • The SPRINT PNS treatment group (n=18) demonstrated a 47 percent improvement in walking ability measured by a six-minute walk test whereas the placebo group (n=20) demonstrated a nine percent decrease.